Allarity Therapeutics Reports Positive Phase 2 Trial Data
DENVER, Colo., Jun 25, 2024 (247marketnews.com)- Allarity Therapeutics, Inc. (NASDAQ:ALLR) reported that multiple patients in its Phase 2 stenoparib clinical trial, for advanced recurrent ovarian cancer, have exceeded 30 weeks of treatment.
Thomas Jensen, CEO of Allarity Therapeutics, stated, “The continued durability of clinical benefit from stenoparib furthers our enthusiasm for stenoparib for patients who traditionally have limited treatment options and often only a few months of continued life expectancy. We continue to see patients maintain their quality of life with minimal side effects for extended periods.
“Not only does the safety profile stand out when compared to chemotherapies, which is often the alternative for this patient group, but the safety metrics are indeed also favorable when compared to first-generation PARP inhibitors. As we see it, stenoparib may represent the next-generation alternative for advanced ovarian cancer patients. Therefore, we are aggressively working with Dr. Moore and other leading experts to design a trial that will help advance and quicken stenoparib’s clinical progress toward registration with the FDA.”
Kathleen N. Moore, MD, MS, and Principal Investigator for the current Allarity trial, commented, “Inhibition of poly-ADP-ribose polymerase or PARP has been transformational for the treatment of ovarian cancer with first-generation agents significantly improving progression-free and overall survival especially among patients with biomarkers for their use. However, there are a significant number of patients who either don’t benefit at all from inhibition of PARP or only modestly and for them, continual development of next-generation agents remains a high priority. The promising results observed with stenoparib – particularly with the tolerability demonstrated so far, warrant further development of this drug. I look forward to continuing the discussions with the team at Allarity to refine the future trial design and subsequently continue to investigate the potential of this novel PARP/Tankyrase inhibitor.”
About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.
24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.
CONTACT:
24/7 Market News
Editor@247marketnews.com
Related news for (ALLR)
- Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months
- 24/7 Market News Snapshot 22 September, 2025 – Allarity Therapeutics, Inc. Common Stock (NASDAQ:ALLR)
- Biotech Power Hour: Surge Round the Bend
- Power Hour Playbook: Biotech Breakouts, Energy Movers & Niche Innovators to Watch Into the Close
- Breaking News: MoBot’s Latest Update as of 08/26/25 09:00 AM